awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4
Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
P2860
Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4f6d7a5ff215e0b1a2e02a42c995c8e4248e6276
P2860
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.